Menarini Stemline Oncology

Stemline Therapeutics, a subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The company's flagship product, Elzonris (tagraxofusp-erzs), is a first-in-class targeted therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Stemline also markets Orserdu (elacestrant), the first oral selective estrogen receptor degrader (SERD) for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. With a robust pipeline targeting various hematologic malignancies and solid tumors, the company leverages its global infrastructure to bring innovative treatments to cancer patients worldwide. Stemline was acquired by Menarini in 2020, significantly expanding the parent company's presence in the United States and the global oncology market.